Chimeric Therapeutics is trading 5.56% up at A$0.02 following the August 19 cessation of CHM-2101 Phase 1 enrolment and dosing after dose-limiting toxicity in a second Dose Level 3 patient. - The company will not progress CHM-2101 in its current form. - It plans to explore an in-vivo CDH17 approach alongside approximately A$4 million in annual cost reductions.